Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/TUBA1B_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TUBA1B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/TUBA1B_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TUBA1B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/TUBA1B_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TUBA1B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TUBA1B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TUBA1B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TUBA1B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TUBA1B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00307057 | Cervix | CC | cytoskeleton-dependent intracellular transport | 40/2311 | 195/18723 | 7.92e-04 | 6.99e-03 | 40 |
GO:00713533 | Cervix | HSIL_HPV | cellular response to interleukin-4 | 7/737 | 33/18723 | 2.48e-04 | 4.30e-03 | 7 |
GO:00706703 | Cervix | HSIL_HPV | response to interleukin-4 | 7/737 | 36/18723 | 4.38e-04 | 6.51e-03 | 7 |
GO:003070513 | Cervix | N_HPV | cytoskeleton-dependent intracellular transport | 13/534 | 195/18723 | 4.03e-03 | 3.16e-02 | 13 |
GO:00307058 | Endometrium | AEH | cytoskeleton-dependent intracellular transport | 38/2100 | 195/18723 | 4.72e-04 | 4.91e-03 | 38 |
GO:003070514 | Endometrium | EEC | cytoskeleton-dependent intracellular transport | 39/2168 | 195/18723 | 4.40e-04 | 4.58e-03 | 39 |
GO:003070517 | Esophagus | HGIN | cytoskeleton-dependent intracellular transport | 45/2587 | 195/18723 | 3.07e-04 | 5.15e-03 | 45 |
GO:003070518 | Esophagus | ESCC | cytoskeleton-dependent intracellular transport | 133/8552 | 195/18723 | 1.48e-10 | 4.27e-09 | 133 |
GO:00713532 | Liver | Cirrhotic | cellular response to interleukin-4 | 17/4634 | 33/18723 | 8.32e-04 | 6.06e-03 | 17 |
GO:003070511 | Liver | Cirrhotic | cytoskeleton-dependent intracellular transport | 68/4634 | 195/18723 | 9.54e-04 | 6.77e-03 | 68 |
GO:00706702 | Liver | Cirrhotic | response to interleukin-4 | 17/4634 | 36/18723 | 2.82e-03 | 1.63e-02 | 17 |
GO:003070521 | Liver | HCC | cytoskeleton-dependent intracellular transport | 111/7958 | 195/18723 | 3.25e-05 | 3.28e-04 | 111 |
GO:007135311 | Liver | HCC | cellular response to interleukin-4 | 21/7958 | 33/18723 | 1.16e-02 | 4.28e-02 | 21 |
GO:003070510 | Oral cavity | OSCC | cytoskeleton-dependent intracellular transport | 113/7305 | 195/18723 | 6.03e-08 | 1.09e-06 | 113 |
GO:00713535 | Oral cavity | OSCC | cellular response to interleukin-4 | 21/7305 | 33/18723 | 3.63e-03 | 1.51e-02 | 21 |
GO:00706705 | Oral cavity | OSCC | response to interleukin-4 | 21/7305 | 36/18723 | 1.46e-02 | 4.76e-02 | 21 |
GO:007135313 | Oral cavity | LP | cellular response to interleukin-4 | 18/4623 | 33/18723 | 2.26e-04 | 2.41e-03 | 18 |
GO:003070516 | Oral cavity | LP | cytoskeleton-dependent intracellular transport | 68/4623 | 195/18723 | 8.92e-04 | 7.64e-03 | 68 |
GO:007067012 | Oral cavity | LP | response to interleukin-4 | 18/4623 | 36/18723 | 9.03e-04 | 7.72e-03 | 18 |
GO:00307059 | Prostate | BPH | cytoskeleton-dependent intracellular transport | 68/3107 | 195/18723 | 3.78e-10 | 1.98e-08 | 68 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TUBA1B | SNV | Missense_Mutation | | c.1345N>C | p.Glu449Gln | p.E449Q | P68363 | protein_coding | deleterious_low_confidence(0.03) | benign(0.403) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TUBA1B | SNV | Missense_Mutation | rs769034868 | c.785A>C | p.Tyr262Ser | p.Y262S | P68363 | protein_coding | deleterious_low_confidence(0.01) | benign(0.052) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
TUBA1B | SNV | Missense_Mutation | | c.346N>C | p.Asp116His | p.D116H | P68363 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.792) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
TUBA1B | SNV | Missense_Mutation | rs769034868 | c.785N>C | p.Tyr262Ser | p.Y262S | P68363 | protein_coding | deleterious_low_confidence(0.01) | benign(0.052) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TUBA1B | SNV | Missense_Mutation | rs769034868 | c.785A>C | p.Tyr262Ser | p.Y262S | P68363 | protein_coding | deleterious_low_confidence(0.01) | benign(0.052) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
TUBA1B | SNV | Missense_Mutation | | c.337N>C | p.Glu113Gln | p.E113Q | P68363 | protein_coding | deleterious_low_confidence(0.04) | benign(0.017) | TCGA-GM-A2DO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | CR |
TUBA1B | insertion | Frame_Shift_Ins | novel | c.411_412insACAACTCC | p.Phe138ThrfsTer47 | p.F138Tfs*47 | P68363 | protein_coding | | | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TUBA1B | SNV | Missense_Mutation | | c.1348G>C | p.Glu450Gln | p.E450Q | P68363 | protein_coding | deleterious_low_confidence(0.05) | benign(0.003) | TCGA-FU-A3YQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
TUBA1B | SNV | Missense_Mutation | | c.922N>T | p.Arg308Cys | p.R308C | P68363 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.952) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
TUBA1B | SNV | Missense_Mutation | novel | c.367N>T | p.Arg123Cys | p.R123C | P68363 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.794) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10376 | TUBA1B | DRUGGABLE GENOME | inhibitor | CHEMBL538943 | VINORELBINE TARTRATE | |
10376 | TUBA1B | DRUGGABLE GENOME | | PACLITAXEL | PACLITAXEL | 23631389,25369367,25768699,24457094,22595423,23313639,17887662,23387901,19758808,23725535,24953821 |
10376 | TUBA1B | DRUGGABLE GENOME | | MAYTANSINOL | MAYTANSINOL | 563462 |
10376 | TUBA1B | DRUGGABLE GENOME | inhibitor | CHEMBL1201748 | CABAZITAXEL | |
10376 | TUBA1B | DRUGGABLE GENOME | inhibitor | CHEMBL289351 | FOSBRETABULIN DISODIUM | |
10376 | TUBA1B | DRUGGABLE GENOME | | VORINOSTAT | VORINOSTAT | 20491440 |
10376 | TUBA1B | DRUGGABLE GENOME | inhibitor | CHEMBL3545252 | DOCETAXEL | |
10376 | TUBA1B | DRUGGABLE GENOME | | COLCHICINE | COLCHICINE | 23750455,25805446,24502232,25061803,25937236,24773591,25938266 |
10376 | TUBA1B | DRUGGABLE GENOME | | COMBRETASTATIN A4 | COMBRETASTATIN A4 | 23631389,16913727,22543234,25584687,24669888,17765552,25192811 |
10376 | TUBA1B | DRUGGABLE GENOME | | CHEMBL2105643 | FOSBRETABULIN TROMETHAMINE | |